TuHURA Files S-1/A for Resale of 9.3M Shares Post-Kineta Merger

TL;DR

**HURA's S-1/A is a green light for early investors to cash out, putting pressure on the stock while the company pivots with its new Kineta assets and a critical Phase 3 trial.**

AI Summary

TuHURA Biosciences, Inc. (HURA) filed an S-1/A on September 18, 2025, primarily for the resale of up to 9,321,545 shares of common stock by selling stockholders, including 4,570,629 existing shares and 4,750,916 shares issuable upon warrant exercise. The company will not receive proceeds from these resales, but will receive proceeds if warrants are exercised for cash. HURA completed the acquisition of Kineta, Inc. on June 30, 2025, gaining rights to TBS-2025, a VISTA-inhibiting monoclonal antibody. A private placement on June 2, 2025, raised approximately $12.6 million through the sale of 4,759,309 shares and equal warrants at a combined effective price of $2.65 per unit. This funding was received in tranches, with $2.23 million on June 2, 2025, another $2.23 million on June 9, 2025, following FDA notification regarding a partial clinical hold lift, $2.23 million on June 24, 2025, upon initiation of the Phase 3 trial for IFx-Hu2.0, and $2.23 million on June 30, 2025, tied to the Kineta merger closing. An additional $3.2 million from deferral investors was purchased on September 5, 2025, in exchange for extending 2024 warrants to December 31, 2030. Proceeds are earmarked for Kineta acquisition expenses, funding the IFx-2.0 Phase 3 trial, advancing TBS-2025 to a Phase 2 trial, and general working capital.

Why It Matters

This S-1/A filing signals a significant liquidity event for early investors and selling stockholders, potentially increasing the float of HURA shares on NASDAQ and impacting market price. The company's strategic shift, marked by the June 30, 2025 Kineta acquisition and the initiation of a Phase 3 trial for IFx-Hu2.0, positions it more firmly in the competitive immuno-oncology space, particularly against established players in Merkel cell carcinoma and AML. Investors should monitor the impact of these resales on HURA's stock performance and the company's ability to execute on its clinical development timelines for IFx-Hu2.0 and TBS-2025. Employees and customers will be watching for successful clinical outcomes that validate the company's expanded pipeline.

Risk Assessment

Risk Level: high — The risk level is high due to the nature of a clinical-stage immuno-oncology company, as highlighted by the 'Risk Factors' section starting on page 5. The company's ability to generate revenue is 'materially impaired' if regulatory approvals for product candidates are delayed or not obtained, a common challenge in biotech. Furthermore, the S-1/A is for resale by selling stockholders, meaning the company will not receive proceeds from these sales, limiting direct capital infusion from this specific offering, though it will receive proceeds from warrant exercises.

Analyst Insight

Investors should exercise caution and thoroughly review the 'Risk Factors' section, particularly regarding clinical trial success and regulatory approvals. Monitor the volume and price action of HURA shares as selling stockholders begin to offload their 9,321,545 shares, as this could create downward pressure. Consider the company's cash burn rate against the $12.6 million raised from the private placement and the potential proceeds from warrant exercises to assess its runway for the Phase 3 IFx-Hu2.0 trial and Phase 2 TBS-2025 trial.

Key Numbers

• 9,321,545 — Shares of common stock (Total shares offered for resale by selling stockholders)
• 4,570,629 — Shares of common stock (Existing shares offered for resale)
• 4,750,916 — Shares of common stock (Shares issuable upon warrant exercise offered for resale)
• $2.43 — Last reported sale price (HURA common stock price on September 17, 2025)
• $12.6 million — Aggregate offering amount (Raised from the June 2, 2025 private placement)
• $3.3125 — Warrant exercise price (Per share exercise price for warrants issued in the private placement)
• June 30, 2025 — Acquisition date (Date of Kineta, Inc. acquisition)
• December 31, 2030 — Warrant expiration date (Extended expiration date for 2024 warrants)
• $3.2 million — Final Tranche Offering Amount (Purchased by Deferral Investors on September 5, 2025)
• 60 calendar days — Registration statement filing deadline (Following the Initial Closing of the private placement)

Key Players & Entities

• TuHURA Biosciences, Inc. (company) — Registrant and clinical stage immuno-oncology company
• Kineta, Inc. (company) — Acquired company on June 30, 2025
• James Bianco (person) — Chief Executive Officer of TuHURA Biosciences, Inc.
• Curt P. Creely (person) — Legal counsel from Foley & Lardner LLP
• Securities and Exchange Commission (regulator) — Regulatory body overseeing the filing
• NASDAQ Capital Market (regulator) — Stock exchange where HURA is listed
• Food and Drug Administration (FDA) (regulator) — Regulatory body for clinical trials and product approvals
• Pranabio Investments LLC (company) — Deferral Investor in the private placement
• Garden Street House, LLC (company) — Deferral Investor in the private placement
• Thomas C. Mollick (person) — Deferral Investor in the private placement

FAQ

Risk Factors

• Dilution from outstanding options and warrants [medium — financial]: As of September 11, 2025, there are 6,488,116 shares issuable upon exercise of stock options at a weighted price of $5.13 and 13,197,640 shares issuable upon exercise of warrants at a weighted price of $4.58. This represents a significant potential dilution to existing shareholders.
• Dependence on Kineta acquisition and TBS-2025 development [high — operational]: The company's strategy is heavily reliant on the successful integration of Kineta, Inc. and the advancement of its lead candidate, TBS-2025. Any delays or failures in these areas could materially impact the company's prospects.
• Clinical hold risks for drug development [high — regulatory]: The company has experienced partial clinical holds in the past, indicating potential regulatory hurdles in the development of its drug candidates. Future clinical holds could significantly delay or halt development.
• Reliance on future funding and warrant exercises [high — financial]: The company has raised capital through private placements and is relying on warrant exercises and potential future financings to fund its operations and clinical trials. Failure to secure adequate funding could jeopardize its development plans.
• Competition in the oncology and immunology space [medium — market]: The company operates in highly competitive therapeutic areas, facing established pharmaceutical companies and emerging biotechs. Success depends on differentiating its pipeline and demonstrating clinical efficacy.

Industry Context

TuHURA Biosciences operates in the highly competitive biopharmaceutical sector, focusing on oncology and immunology. The industry is characterized by significant R&D investment, long development timelines, and stringent regulatory oversight. Key trends include the increasing focus on targeted therapies, immuno-oncology, and novel biologics like monoclonal antibodies.

Regulatory Implications

The company faces significant regulatory scrutiny inherent in drug development. Past partial clinical holds indicate potential challenges with the FDA, and any future holds could severely impact development timelines and costs. Successful navigation of FDA requirements is critical for advancing TBS-2025 and other pipeline assets.

What Investors Should Do

1. Monitor clinical trial progress for IFx-Hu2.0 and TBS-2025.
2. Assess the impact of potential share dilution.
3. Evaluate the company's cash runway and future financing needs.
4. Review the competitive landscape for VISTA inhibitors and other oncology assets.

Key Dates

• 2025-06-30: Acquisition of Kineta, Inc. — Gained rights to TBS-2025, a VISTA-inhibiting monoclonal antibody, and significantly expanded the company's pipeline.
• 2025-06-02: Initial closing of private placement — Raised $2.23 million, with subsequent tranches tied to clinical and merger milestones, providing crucial funding.
• 2025-09-18: Filing of S-1/A for resale of shares — Provides liquidity for selling stockholders and outlines the current share structure and potential dilution.
• 2025-09-05: Deferral investor purchase — Raised an additional $3.2 million by extending warrant expiration dates, bolstering cash reserves.
• 2030-12-31: Extended warrant expiration date — Provides longer-term capital structure clarity for certain warrants.

Glossary

S-1/A

An amended registration statement filed with the SEC, typically used to update or correct information in a previously filed S-1. (This filing provides updated information on the company's financial condition, business operations, and risks, particularly concerning the resale of shares.)

Warrants

Securities that give the holder the right, but not the obligation, to purchase a company's stock at a specified price (exercise price) before a certain expiration date. (A significant number of shares are issuable upon warrant exercise, impacting potential dilution and future capital raises.)

Monoclonal Antibody

A type of protein made in a laboratory that can bind to specific targets in the body, often used in cancer therapy. (TBS-2025, a key asset acquired through the Kineta merger, is a monoclonal antibody targeting VISTA.)

VISTA

A protein that plays a role in immune suppression, particularly in the tumor microenvironment. Inhibiting VISTA can potentially enhance anti-tumor immune responses. (TBS-2025's mechanism of action involves inhibiting VISTA, aiming to treat cancer.)

Private Placement

A sale of securities directly to a small group of institutional or accredited investors, rather than through a public offering. (The company recently raised $12.6 million through a private placement, which is a key source of its current funding.)

Clinical Hold

A temporary suspension of a clinical trial by a regulatory authority, such as the FDA, due to safety concerns or other issues. (The company has experienced partial clinical holds, highlighting potential regulatory challenges in drug development.)

Year-Over-Year Comparison

This S-1/A filing follows a period of significant corporate activity, including the acquisition of Kineta, Inc. and a private placement that raised approximately $12.6 million. Compared to previous filings, this document details the integration of Kineta's assets, particularly TBS-2025, and outlines the capital structure post-financing and warrant extensions. New risks related to the acquired assets and ongoing clinical development are highlighted, alongside the potential dilution from a large number of outstanding warrants and options.

Key Financial Figures

• $0.001 — 5 shares of our common stock, par value $0.001 per share, comprising up to (i) 4,570,6
• $2.43 — common stock on September 17, 2025 was $2.43 per share. Investing in shares of our
• $3.3125 — of common stock at an exercise price of $3.3125 (the "Warrants"), for an aggregate offe
• $12.6 million — regate offering amount of approximately $12.6 million. The combined effective offering price
• $2.65 — ccompanying Warrant in the Offering was $2.65. Pursuant to the Securities Purchase
• $2.23 million — g in four equal tranches, as follows: $2.23 million was purchased on June 2, 2025 (the "Ini
• $8.9 million — ger. In addition to the approximately $8.9 million that was purchased in four tranches thr
• $3.7 million — ities Purchase Agreement, approximately $3.7 million of the Offering (the "Final Tranche Off
• $3.2 million — to immediately purchase an aggregate of $3.2 million of the Final Tranche Offering Amount in
• $5.7528 — ct of (A) such fractional share and (B) $5.7528. Implications of Being a Smaller Repo
• $250 million — eld by non-affiliates equals or exceeds $250 million as of the end of that year's second fis
• $100 million — our annual revenues equaled or exceeded $100 million during such completed fiscal year and t
• $700 million — eld by non-affiliates equals or exceeds $700 million as of the end of that year's second fis
• $5.13 — tanding at a weighted exercise price of $5.13 per share; 9,328,113 shares of common
• $4.58 — tanding at a weighted exercise price of $4.58 per share; up to 1,539,958 shares of

Filing Documents

• d898723ds1a.htm (S-1/A) — 6307KB
• d898723dex231.htm (EX-23.1) — 1KB
• d898723dex232.htm (EX-23.2) — 1KB
• d898723dex233.htm (EX-23.3) — 1KB
• g898723g00i31.jpg (GRAPHIC) — 113KB
• g898723g01a56.jpg (GRAPHIC) — 149KB
• g898723g01a63.jpg (GRAPHIC) — 70KB
• g898723g01a65.jpg (GRAPHIC) — 187KB
• g898723g01a70.jpg (GRAPHIC) — 169KB
• g898723g03a68.jpg (GRAPHIC) — 34KB
• g898723g05v55.jpg (GRAPHIC) — 250KB
• g898723g39y20.jpg (GRAPHIC) — 143KB
• g898723g62b62.jpg (GRAPHIC) — 120KB
• g898723g95o33.jpg (GRAPHIC) — 148KB
• 0001193125-25-207395.txt ( ) — 24895KB
• hura-20250630.xsd (EX-101.SCH) — 3041KB
• d898723ds1a_htm.xml (XML) — 3609KB

USE OF PROCEEDS

USE OF PROCEEDS 49 DIVIDEND POLICY 50

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 99 MANAGEMENT 117

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 123 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 136 PRINCIPAL STOCKHOLDERS 139

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 141 SELLING STOCKHOLDERS 144 PLAN OF DISTRIBUTION 152 LEGAL MATTERS 155 EXPERTS 155 WHERE YOU CAN FIND MORE INFORMATION 156 INDEX TO FINANCIAL STATEMENTS F-1 Please read this prospectus carefully. It describes our business, financial condition, results of operations and prospects, among other things. We are responsible for the information contained in this prospectus and in any free-writing prospectus we have authorized. Neither we nor the underwriters have authorized anyone to provide you with different information, and neither we nor the underwriters take responsibility for any other information others may give you. Neither we nor the underwriters are making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is accurate only as of the date on the front of this prospectus, regardless of the time of delivery of this prospectus or any sale of securities. You should not assume that the information contained in this prospectus is accurate as of any date other than its date. i Table of Contents ABOUT THIS PROSPECTUS Unless the context otherwise requires, references in this prospectus to "Company," "TuHURA," "we," "us," "our," and "ours" refer to TuHURA Biosciences, Inc., and its subsidiaries where the context so requires. This prospectus relates to the resale from time to time by the selling stockholders named in this prospectus of up to 9,321,545 shares of common stock. The exhibits to the registration statement of which this prospectus is a part contain the full text of certain contracts and other important documents that we have summarized in this prospectus. Since these summaries may not contain all the information that you may find important in deciding whether to acquire or purchase common stock offered by this prospectus, you should review the full text of these documents. The registration statement and the e

Use of proceeds

Use of proceeds We will not receive any proceeds from the sale of shares being sold by the selling stockholders. We will, however, receive proceeds on the exercise by the selling stockholders of outstanding warrants for shares of our common stock covered by this prospectus if the warrants are exercised for cash. See "Use of Proceeds." Nasdaq Capital Market Symbol "HURA".

Risk factors

Risk factors Investing in our common stock involves a high degree of risk. See "Risk Factors" beginning on page 5 of this prospectus for a discussion of factors you should carefully consider before investing in our common stock. The number of shares of common stock to be outstanding after the Offering is based on 51,103,535 shares of common stock outstanding at September 11, 2025 (assuming exercise by the selling stockholders of all warrants being offering), excludes the following as of September 11, 2025: 6,488,116 shares of common stock issuable upon the exercise of stock options outstanding at a weighted exercise price of $5.13 per share; 9,328,113 shares of common stock reserved for future issuance under our TuHURA Biosciences, Inc. 2024 Equity Incentive Plan; 13,197,640 shares of common stock issuable upon the exercise of warrants outstanding at a weighted exercise price of $4.58 per share; up to 1,539,958 shares of common stock reserved for issuance that may be issued pursuant to the terms of the Contingent Value Rights Agreement, dated as of October 18, 2024, between the Company (f/k/a Kintara Biosciences, Inc.) and Equiniti Trust Company, LLC; and up to 1,129,885 shares reserved for issuance as delayed merger consideration to the Kineta stockholders, subject to adjustment for certain losses incurr

View Full Filing

View this S-1/A filing on SEC EDGAR